IMMUNOMODULATION BY IMIQUIMOD IN PRIMARY MELANOMA

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 具体目标 黑色素瘤是影响人类的最常见的肿瘤之一，也是最致命的皮肤癌。2006年，估计有62,000名美国人被诊断为黑色素瘤，死亡率估计为79001。虽然局限期诊断的肿瘤5年生存率良好，但区域和远处转移的5年生存率分别为令人沮丧的%和16%。目前治疗恶性黑色素瘤的标准包括手术切除和前哨淋巴结(SLN)活检以达到分期的目的。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. SPECIFIC AIMS Melanoma is one of the most common tumors affecting humans and the deadliest of skin cancers. In 2006, an estimated 62,000 Americans were diagnosed with melanoma, with an estimated mortality incidence of 79001. And although 5 year survival rates for disease diagnosed at the localized stage are favorable, the 5 year survival rates for regional and distant metastases are a dismal 64% and 16%, respectively. Current standard of care for malignant melanoma includes surgical excision and sentinel lymph node (SLN) biopsy for staging purposes.